mRNA Provides Significant Long-Term Investment Opportunities

Investment Insights

The success of the mRNA-based vaccine for the COVID-19 virus established that mRNA technology is highly effective in improving the body’s immune response. Messenger ribonucleic acid (mRNA) vaccines are faster and easier to mass-produce than traditional vaccines. This feature enabled biopharma companies to invest in and produce mRNA-based COVID-19 vaccines on a large scale, which was necessary to combat the pandemic. But how does one keep fundamentals over frenzy and identify the best-placed beneficiaries? And will the capital raising activity continue to remain that strong? 

Key Takeaways:
•    The mRNA vaccine technology promises a huge growth potential to biopharma companies.
•    After the recent success of mRNA vaccines to fight against the COVID-19 virus, companies are participating in M&A and fundraising activities.
•    While mRNA is still in its infancy stage, the fight against COVID-19 has served as a significant testing ground for the technology.
•    Companies are now exploring the possibility as well as the benefits of mRNA vaccines to treat other diseases.

To know more...


Related Topics

SG Analytics_Investment Insigts_Whitepaper_China Real Estate

White Papers

China Real Estate - In Desperate Need of More Policy...

China’s real estate sector has been significantly impacted by the introduction of the three red lines policy, eventually leading to a liquidity crunch...

SG Analytics Whitepaper European Defence Spending

White Papers

The Super Cycle in European Defence Spending

Regardless of its errors in judgment, political blunders, and glaring lack of soft power, Russia will only be able to win in Ukraine if it has a military...

Whitepaper China Real Estate 3

White Papers

China Real Estate Signs of Moderation in Free Fall

Since the announcement of China's three red lines policy in August 2020, the real estate sector has been heavily impacted by it, eventually leading to a...

We bring comprehensive data driven insights to everyone, everywhere